Global Non-Small Cell Lung Cancer Market

Global Non-Small Cell Lung Cancer Market Size, Share, Growth Analysis, By Therapy(Targeted Therapy,Immunotherapy) - Industry Forecast 2022-2028


Report ID: SQMIG25K2005 | Region: Global | Published Date: September, 2022 | Pages: 165 | Tables: 36 | Figures: 72

Global Non-Small Cell Lung Cancer Market Insights

Global non-small cell lung cancer market was valued at USD11.43 billion in 2021, and it is predicted to reach USD12.2 billion by 2028. The market is expected to grow at a CAGR of 6.3 % during the forecast period (2022–2028).

The introduction of immune checkpoint inhibitors (ICIs) into the first-line context is one of the main drivers influencing market revenue growth. Eighty to eighty-five percent of lung cancer occurrences worldwide are non-small cell lung cancer, and because of this high percentage, the majority of market leaders are concentrating on constantly developing new therapies and enhancing the effectiveness of already-available medications. The market expansion is also attributable to lung cancer's notoriety as one of the most prevalent malignancies that causes a sizable number of fatalities worldwide. Increased non-small cell lung cancer diagnoses and greater public knowledge of the condition in developed and developing nations both contribute to the growth of the non-small cell lung cancer market. The inclusion of non-small cell cancer medicines in the pipelines of key market participants, together with increased investment in research and development activities by top businesses, is boosting the global market's growth.

To get more reports on the above market click here to Buy The Report

Global Non-Small Cell Lung Cancer Market Segmental Analysis

The global non-small cell lung cancer market is segmented based on therapy, region. Based on therapy it is categorized into targeted therapy, chemotherapy, and immunotherapy. Based on region it is categorized into: North America, Europe, Asia-Pacific, South America, and MEA.

Analysis by Pest Type 

The targeted therapy segment dominated the global non-small cell lung cancer Market in the year 2021 with more than 51% of market share. A type of treatment called targeted therapy employs medications or other chemicals to target particular cancer cells. Compared to chemotherapy or radiation therapy, these treatments typically don't kill normal cells as much.

To get detailed analysis on other segments, Request For Sample Report

Global Non-Small Cell Lung Cancer Market Regional Insights

By region, the non-small cell lung cancer market is spread across North America, Europe, Asia-Pacific, and LAMEA. North America earned USD 5.6 billion in revenue from the non-small cell lung cancer therapies market in 2021, and it is projected that over the forecast period, it would hold a leading position of this market. The fact that between 80% and 85% of all occurrences of lung cancer are NSCLC is the main reason for the market's considerable and rapid expansion.

The acceptance of non-small cell lung cancer therapies is anticipated to increase with the rise in lung cancer risk factors, such as the percentage of smokers in the general population and exposure to toxins like asbestos and air pollution. Along with the other crucial medicines of chemotherapy and targeted therapy, the use of sophisticated immunotherapies is expanding in wealthy nations.

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Global Non-Small Cell Lung Cancer Market Dynamics

Driver

  • Among the factors driving the growth of the NSCLC market are the rising rates of lung cancer caused by smoking, air pollution (asbestos, cadmium, and radon), HIV infection, and population expansion.
  • The market is anticipated to develop as a result of the regulatory authorities' increasing approval of novel drugs for the treatment of non-small cell lung cancer. The market's major players are concentrating their efforts on R&D spending in order to meet the growing demand for treatments for non-small cell lung cancer.

Restraint 

  • The expensive nature of treatment is one of the main obstacles for the non-small cell lung cancer market. Chemotherapy, surgery, targeted therapies, radiation therapy, and immunotherapy are all effective treatments for the disease but are also highly expensive. As a result, market expansion is anticipated to be constrained by the high cost of the treatment.

Speak to one of our ABIRAW analyst for your custom requirements before the purchase of this report

Global Non-Small Cell Lung Cancer Market Competitive Landscape

  • Different techniques are being used by players to broaden their product offerings and expand their geographic reach in response to the demand for lung cancer therapies. Product innovation, alliances and partnerships, and mergers are a few of the primary tactics used by participants in the worldwide lung cancer treatments market. The major players in the market are GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, Novartis AG, Eli Lilly And Company., Astrazeneca, Pfizer Inc., Takeda Pharmaceutical Company Limited., Ono Pharmaceutical Co., Ltd., Boehringer Ingelheim International Gmbh, Merck & Co., Inc., Celgene Corporation, Amgen Inc., Sanofi, Johnson & Johnson Services, Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Allergan, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company and Astellas Pharma Inc.

Top Players in the Global Non-Small Cell Lung Cancer Market 

  • GlaxoSmithKline plc.(US)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Novartis AG, (Switzerland)
  • Eli Lilly And Company.(US)
  • Astrazeneca, Pfizer Inc. (UK)
  • Takeda Pharmaceutical Company Limited.(Japan)
  • Ono Pharmaceutical Co., Ltd.(Japan)
  • Boehringer Ingelheim International Gmbh(Germany)
  • Merck & Co., Inc.(US)
  • Celgene Corporation, Amgen Inc.(California)
  • Sanofi (France)
  • Johnson & Johnson Services, Inc. (US)
  • Sun Pharmaceutical Industries Ltd.(Mumbai)
  • Dr. Reddy’s Laboratories Ltd. (Hyderabad)
  • Allergen (Ireland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Bristol-Myers Squibb Company(US)
  • Astellas Pharma Inc(Japan)

Recent Developments

  • In May 2020, Pfizer Inc.'s LORVIQUA medication, which is indicated for adult patients with advanced non-small cell lung cancer who have tested positive for ALK and have previously received treatment with alectinib or ceritinib as the first anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) therapy, received a favourable opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP).

Global Non-Small Cell Lung Cancer Key Market Trends

  • The expansion of the non-small cell lung cancer treatments market is also being aided by an increase in diagnoses of non-small cell lung cancer and an increase in awareness in both developed and developing regions. The inclusion of non-small cell cancer treatments in the pipelines of leading market participants, along with increased spending by major players in research and development activities, are also propelling the market expansion internationally.

Global Non-Small Cell Lung Cancer Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates and Analyses the Data collected by means of Primary Exploratory Research backed by the robust Secondary Desk research.

According to our analysis, by therapy, the targeted therapy segment has the largest share of the market. Region-wise, the North America region accounted highest market share with more than 80% of total market revenue.

Report Metric Details
Market size value in 2028 11.43 billion in
Growth Rate 6.3%
Base year 2021
Forecast period 2022–2028
Forecast Unit (Value) 11.43 In
Segments covered
  • Therapy
    • Targeted Therapy,Immunotherapy,Chemotherapy
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • GlaxoSmithKline plc.(US)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Novartis AG, (Switzerland)
  • Eli Lilly And Company.(US)
  • Astrazeneca, Pfizer Inc. (UK)
  • Takeda Pharmaceutical Company Limited.(Japan)
  • Ono Pharmaceutical Co., Ltd.(Japan)
  • Boehringer Ingelheim International Gmbh(Germany)
  • Merck & Co., Inc.(US)
  • Celgene Corporation, Amgen Inc.(California)
  • Sanofi (France)
  • Johnson & Johnson Services, Inc. (US)
  • Sun Pharmaceutical Industries Ltd.(Mumbai)
  • Dr. Reddy’s Laboratories Ltd. (Hyderabad)
  • Allergen (Ireland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Bristol-Myers Squibb Company(US)
  • Astellas Pharma Inc(Japan)
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Global Non-Small Cell Lung Cancer Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Global Non-Small Cell Lung Cancer Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Global Non-Small Cell Lung Cancer Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Global Non-Small Cell Lung Cancer Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Global Non-Small Cell Lung Cancer Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Global Non-Small Cell Lung Cancer Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$3,500
BUY NOW GET SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

SPEAK TO AN ANALYST

FAQ's

Global non-small cell lung cancer market was valued at USD11.43 billion in 2021, and it is predicted to reach USD12.2 billion by 2028. The market is expected to grow at a CAGR of 6.3 % during the forecast period (2022–2028).

Top Players in the Global Non-Small Cell Lung Cancer Market  'GlaxoSmithKline plc.(US)', 'F. Hoffmann-La Roche Ltd (Switzerland)', 'Novartis AG, (Switzerland)', 'Eli Lilly And Company.(US)', 'Astrazeneca, Pfizer Inc. (UK)', 'Takeda Pharmaceutical Company Limited.(Japan)', 'Ono Pharmaceutical Co., Ltd.(Japan)', 'Boehringer Ingelheim International Gmbh(Germany)', 'Merck & Co., Inc.(US)', 'Celgene Corporation, Amgen Inc.(California)', 'Sanofi (France)', 'Johnson & Johnson Services, Inc. (US)', 'Sun Pharmaceutical Industries Ltd.(Mumbai)', 'Dr. Reddy’s Laboratories Ltd. (Hyderabad)', 'Allergen (Ireland)', 'Teva Pharmaceutical Industries Ltd. (Israel)', 'Bristol-Myers Squibb Company(US)', 'Astellas Pharma Inc(Japan) '

Among the factors driving the growth of the NSCLC market are the rising rates of lung cancer caused by smoking, air pollution (asbestos, cadmium, and radon), HIV infection, and population expansion.

The expansion of the non-small cell lung cancer treatments market is also being aided by an increase in diagnoses of non-small cell lung cancer and an increase in awareness in both developed and developing regions. The inclusion of non-small cell cancer treatments in the pipelines of leading market participants, along with increased spending by major players in research and development activities, are also propelling the market expansion internationally.

By region, the non-small cell lung cancer market is spread across North America, Europe, Asia-Pacific, and LAMEA. North America earned USD 5.6 billion in revenue from the non-small cell lung cancer therapies market in 2021, and it is projected that over the forecast period, it would hold a leading position of this market. The fact that between 80% and 85% of all occurrences of lung cancer are NSCLC is the main reason for the market's considerable and rapid expansion.

Speak With Our Analyst

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Non-Small Cell Lung Cancer Market

Product ID: SQMIG25K2005

$3,500
BUY NOW GET SAMPLE